Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed

NCT ID: NCT06109935

Last Updated: 2025-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-04

Study Completion Date

2026-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to investigate the safety and effectiveness of Sogroya® in children with short stature due to growth hormone deficiency where epiphysial discs are not closed under real-world clinical practice in Japan. The study will last for about 1 year (at shortest) to 3 years (at longest) depending on when the participant takes part in the study. The participant will be asked to answer questionnaire(s) about how they feel about the growth hormone (GH) product treatment once during the study (at about 3 months after starting the Sogroya® treatment) and about 3 months after starting the Sogroya® treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Growth Hormone Deficiency in Children

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with GHD

Participants will be treated with commercially available Sogroya® according to routine clinical practice at the discretion of the treating physician. Administration will be according to the approved product labelling. The decision to treat a participant with Sogroya® is made at the treating physician's discretion before and independently from the decision to include the patient in this study.

Somapacitan

Intervention Type DRUG

Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Somapacitan

Sogroya® treatment regimen will be in accordance with the approved product labelling in Japan.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sogroya®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
2. The decision to initiate treatment with commercially available Sogroya® has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study. Both GH treatment naïve and non-naïve children are eligible.
3. Male or female age 0 to 18 years (exclusive) at the time of signing informed consent.
4. Diagnosis with short stature due to GHD where epiphysial discs are not closed according to local normal clinical practice.

Exclusion Criteria

1. Previous participation in this study. Participation is defined as having given informed consent in this study.
2. Treatment with any investigational drug within 30 days prior to baseline (the starting date of Sogroya® treatment).
3. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
4. Contraindication described in approved product labelling in Japan.

1. Patients with hypersensitivity to the active substance or to any of the excipients
2. Patients with malignant tumour
3. Female patients who are either pregnant or likely to be pregnant
Minimum Eligible Age

0 Years

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novo Nordisk A/S

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Clinical Transparency dept. 2834

Role: STUDY_DIRECTOR

Novo Nordisk A/S

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hoshigaoka Seicho Clinic_Pediatrics

Aichi, , Japan

Site Status

Iwayama Pediatric_Pediatrics

Aichi, , Japan

Site Status

Asai Clinic_Pediatrics

Aichi, , Japan

Site Status

Mutsu general hospital

Aomori, , Japan

Site Status

Asahikawa Medical Univ. Hospital_Pediatrics

Asahikawa, Hokkaido, , Japan

Site Status

Beppu Medical Center

Beppu-shi, Oita-ken, , Japan

Site Status

Inomata Child Clinic_Pediatrics

Chiba, , Japan

Site Status

Seirei Sakura Citizen Hospital_Pediatrics

Chiba, , Japan

Site Status

Kurume University Hospital, Pediatrics

Fukuoka, , Japan

Site Status

Fukuoka University Hospital

Fukuoka-shi, Fukuoka-ken, , Japan

Site Status

Kyushu University Hospital

Fukuoka-shi, Fukuoka, , Japan

Site Status

Gifu University Hospital

Gifu, , Japan

Site Status

Ota Memorial Hospital_Pediatrics

Gunma, , Japan

Site Status

Kato Clinic

Hachioji-shi, Tokyo-to, , Japan

Site Status

Hamamatsu University Hospital

Hamamatsu-shi, Shizuoka, , Japan

Site Status

Hello Clinic

Higashimatsuyama-shi, Saitama-ken, , Japan

Site Status

Japanese Red Cross Society Himeji Hospital

Himeji-shi, Hyogo-ken, , Japan

Site Status

Yonekura Child Clinic_Pediatrics

Hiroshima, , Japan

Site Status

Hyogo prefectural kobe children's hospital

Hyōgo, , Japan

Site Status

Nakasako Kids Clinic_Pediatrics

Hyōgo, , Japan

Site Status

Nagai Kids Clinic_Pediatrics

Hyōgo, , Japan

Site Status

Sunsun Kodomo Clinic

Ichikawa-shi, Chiba-ken, , Japan

Site Status

Komatsu Municipal Hospital_Pediatrics

Ishikawa, , Japan

Site Status

Fukushima Seishi Ryougoen

Iwaki-shi, Fukushima-ken, , Japan

Site Status

Shimane University Hospital_Pediatrics

Izumo-shi, Shimane-ken, , Japan

Site Status

Kagoshima University hospital_Pediatrics

Kagoshima, , Japan

Site Status

University Hospital Kyoto Prefectual University of Medicine

Kamigyo-ku, Kyoto, , Japan

Site Status

Muza Kawasaki Pediatric Clinic_Pediatrics

Kanagawa, , Japan

Site Status

Oguchi Higashi Hospital_Pediatrics

Kanagawa, , Japan

Site Status

Hanamaru Kids Clinic_Pediatrics

Kanagawa, , Japan

Site Status

Odawara Municipal Hospital_Diabetes and Endocrinology

Kanagawa, , Japan

Site Status

Nippon Medical School Musashikosugi Hospital_Neurological Surgery

Kawasaki-shi, Kanagawa-ken, , Japan

Site Status

Hospital of the University of Occupational And Environmental Health Japan, Pediatrics

Kitakyusyu-shi, Fukuoka, , Japan

Site Status

Mominoki Hospital, Pediatrics

Kochi-shi, Kochi, , Japan

Site Status

Kumamoto University Hospital, Pediatrics

Kumamoto-shi, Kumamoto, , Japan

Site Status

Ayabe City Hospital

Kyoto, , Japan

Site Status

University of Miyazaki Hospital_Pediatrics

Miyazaki, , Japan

Site Status

Haga Red Cross Hospital

Moka-shi, Tochigi-ken, , Japan

Site Status

Kodomohamirai Morioka Kodomo Clinic

Morioka-shi, Iwate-ken, , Japan

Site Status

Aichi Medical University Hospital

Nagakute-shi, Aichi, , Japan

Site Status

Ina Central Hospital_Nagano

Nagano, , Japan

Site Status

Nagasaki University Hospital_Pediatrics

Nagasaki, , Japan

Site Status

Nagoya City University Hospital, Pediatric

Nagoya, Aichi, , Japan

Site Status

Naha City Hospital

Naha-shi, Okinawa, , Japan

Site Status

University of the Ryukyus Hospital

Nakagami-gun, Okinawa-ken, , Japan

Site Status

Nara Medical University Hospital_Pediatrics

Nara, , Japan

Site Status

Nara Prefecture General Medical Center

Nara-shi, Nara, , Japan

Site Status

Niigata University Medical & Dental Hospital_Pediatrics

Niigata-shi, Niigata, , Japan

Site Status

Hyogo Medical University Hospital_Pediatrics

Nishinomiya-shi, Hyogo-ken, , Japan

Site Status

Iwate Medical University Hospital

Numakunai, , Japan

Site Status

Aichi Children's Health and Medical Center

Obu-shi, Aichi, , Japan

Site Status

Okayama University Hospital_Pediatrics

Okayama, , Japan

Site Status

Asahigawasou Ryouiku Iryou Center_Pediatrics

Okayama, , Japan

Site Status

Chibana Clinic

Okinawa, , Japan

Site Status

Osaka City General Hospital_Endocrinology and Diabetes Mellitus

Osaka, , Japan

Site Status

Kibounomori Clinic

Osaka, , Japan

Site Status

JCHO Osaka Hospital_Pediatric

Osaka, , Japan

Site Status

Saiseikai Suita Hospital

Osaka, , Japan

Site Status

Osaka University Hospital

Osaka, , Japan

Site Status

Yasuhara Children's Clinic

Osaka, , Japan

Site Status

Osaka Women's and Children's Hospital

Osaka, , Japan

Site Status

Kojiya Kodomo clinic

Ota-ku, Tokyo-to, , Japan

Site Status

Okubo Kids Clinic

Ozu-shi, Ehime-ken, , Japan

Site Status

Clinic for Children and Youths_Pediatrics

Saitama, , Japan

Site Status

Sakai Smile Kids Clinic

Sashima-gun, Ibaraki-ken, , Japan

Site Status

JR Sendai Hospital

Sendai-shi, Miyagi-ken, , Japan

Site Status

Shiga university of Medical Science Hospital_Pediatrics

Shiga, , Japan

Site Status

Shiga General Hospital_Diabetes and Endocrinology

Shiga, , Japan

Site Status

My Clinic Ohkubo

Shizuoka, , Japan

Site Status

Shizuoka Saiseikai General Hospital_Pediatrics

Shizuoka, , Japan

Site Status

Hamamatsu Medical Center

Shizuoka, , Japan

Site Status

Iwata City Hospital_Pediatrics

Shizuoka, , Japan

Site Status

Shizuoka Children's Hospital, Department of Diabetes and metabolism

Shizuoka-shi, Shizuoka, , Japan

Site Status

Sakura Kids Clinic_Pediatrics

Tokyo, , Japan

Site Status

National Center for Child Health and Dev, Endo and Metabo

Tokyo, , Japan

Site Status

Tanaka Growth Clinic

Tokyo, , Japan

Site Status

Akiruno Clinic_Pediatrics

Tokyo, , Japan

Site Status

Ehime University Hospital

Toon-shi, Ehime, , Japan

Site Status

Murakami Pediatric and Allergy clinic

Toyama-shi, Toyama-ken, , Japan

Site Status

Fujita Health University Hospital, Pediatrics

Toyoake, Aichi, , Japan

Site Status

Toyohashi Municipal Hospital

Toyohashi-shi, Aichi-ken, , Japan

Site Status

Tendo City Hospital_Pediatrics

Yamagata, , Japan

Site Status

Ikeda Pediatrics Clinic

Yamagata-shi, Yamagata-ken, , Japan

Site Status

Yamaguchi University Hospital_Pediatrics

Yamaguchi, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U1111-1274-4223

Identifier Type: OTHER

Identifier Source: secondary_id

NN8640-5005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.